Arterolane-piperaquine+mefloquine — Competitive Intelligence Brief

Arterolane-piperaquine+mefloquine (Arterolane-piperaquine+mefloquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artemisinin-based combination therapy (ACT). Area: Infectious Disease / Parasitology.

phase 3 Artemisinin-based combination therapy (ACT) Plasmodium falciparum (multiple parasite targets: heme polymerization, mitochondrial function, membrane integrity) Infectious Disease / Parasitology Small molecule

Target snapshot

Arterolane-piperaquine+mefloquine (Arterolane-piperaquine+mefloquine) — University of Oxford. A triple artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms: artemether (artemisinin derivative) damages parasite membranes, piperaquine accumulates in parasites and disrupts hemoglobin digestion, and mefloquine interferes with parasite metabolism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arterolane-piperaquine+mefloquine TARGET	Arterolane-piperaquine+mefloquine	University of Oxford	phase 3	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum (multiple parasite targets: heme polymerization, mitochondrial function, membrane integrity)
AL (Coartem)	AL (Coartem)	Centro de Investigacao em Saude de Manhica	marketed	Artemisinin-based combination therapy (ACT)	Parasite heme metabolism; hemozoin formation
Arterakin (DHA-PPQ)	Arterakin (DHA-PPQ)	National Institute of Malariology, Parasitology and Entomology, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum heme; parasite food vacuole
Arterakine (DHA/piperaquine)	Arterakine (DHA/piperaquine)	Oxford University Clinical Research Unit, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum and other malaria parasites (multiple targets including heme polymerization and oxidative stress pathways)
AS-AQ (Carsucam)	AS-AQ (Carsucam)	Centro de Investigacao em Saude de Manhica	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum (multiple parasite targets)
Dihydroartemisinine-piperaquine	Dihydroartemisinine-piperaquine	Ministry of Public Health, Democratic Republic of the Congo	marketed	Artemisinin-based combination therapy (ACT)	Malaria parasite (Plasmodium species); multiple parasite targets including heme detoxification pathway
Artemether+Lumefantrine (AL)	Artemether+Lumefantrine (AL)	Centers for Disease Control and Prevention	marketed	Artemisinin-based combination therapy (ACT)	Parasite heme metabolism; hemozoin formation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artemisinin-based combination therapy (ACT) class)

1. University of Oxford · 6 drugs in this class
2. Centro de Investigacao em Saude de Manhica · 2 drugs in this class
3. National Institute of Malariology, Parasitology and Entomology, Vietnam · 2 drugs in this class
4. Centers for Disease Control and Prevention · 1 drug in this class
5. Oxford University Clinical Research Unit, Vietnam · 1 drug in this class
6. University Clinical Research Center, Mali · 1 drug in this class
7. Ministry of Public Health, Democratic Republic of the Congo · 1 drug in this class
8. London School of Hygiene and Tropical Medicine · 1 drug in this class
9. Malaria Consortium, Uganda · 1 drug in this class